

AWARD NUMBER: W81XWH-12-1-0474

TITLE: microRNAs to Pathways in Prostate Cancer Progression

PRINCIPAL INVESTIGATOR: Dr. Robert Blelloch

CONTRACTING ORGANIZATION: University of California San Francisco
San Francisco, CA 94118

REPORT DATE: December 2015

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) December 2015		2. REPORT TYPE Final		3. DATES COVERED (From - To) 30Sep2012 - 29Sep2015	
4. TITLE AND SUBTITLE MicroRNAs to Pathways in Prostate Cancer Progression				5a. CONTRACT NUMBER W81XWH-12-1-0474	
				5b. GRANT NUMBER PC110468	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Dr. Robert Blelloch and Dr. Cassandra Belair email: Robert.Blelloch@ucsf.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California San Francisco 1855 Folsom St STE 425 San Francisco CA 94103-4249				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: The overall goal of this funded proposal was to dissect the relationship between the microRNA biogenesis machinery and AKT induced prostate cancer progression using mouse models. Preliminary data showed that removal of a microRNA biogenesis factor, DGCR8, suppressed tumor development in an in vivo prostate epithelium specific PTEN knockout model. Removal of PTEN activates the AKT pathway. Careful phenotypic characterization of PTEN, DGCR8 double knockout prostate epithelial cells showed a defect in expansion of the basal epithelial, a failure to overcome Akt induced senescence, and an associated block in progression from hyperplasia to dysplasia. These connections support a model where basal cell expansion and senescence form barriers for the transition to dysplasia. Furthermore, the central role of DGCR8 suggests that microRNAs are required to suppress senescence and to disregulate basal cell growth. Thus, we measured changes in microRNA levels during tumor progression following PTEN loss identifying six that significantly increase and thirteen that significantly decrease. We had hoped to test these microRNAs individually, but have found in vivo delivery of the microRNAs challenging. However, we will continue these experiments and believe we have a potential solution using shimmimics, a viral delivery system for microRNAs. We plan to continue these studies. We have also shown human relevance by identifying a strong correlation between human tumors with increased Akt activity and increased expression of DGCR8, once again suggesting a requirement for increased microRNA biogenesis with tumor progression. Indeed in situ staining shows high DGCR8 in basal and tumor epithelial cells.					
15. SUBJECT TERMS Prostate Cancer, MicroRNAs, Post-transcriptional Regulation, Progression, Senescence, Basal and Luminal Cells, Transformation.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	34	19b. TELEPHONE NUMBER (include area code)

Table of Contents

INTRODUCTION:..... 4

 STATEMENT OF WORK: 4

KEYWORDS..... 4

ACCOMPLISHMENTS 4

 KEY RESEARCH ACCOMPLISHMENTS..... 4

Specific Aim1:..... 4

Specific Aim2:..... 5

 CONCLUSION:..... 5

 REFERENCES:..... 5

IMPACT 5

CHANGES/PROBLEMS..... 6

REPORTABLE OUTCOMES:..... 6

APPENDICES: 7

SUPPORTING DATA:..... 7

1. INTRODUCTION:

The overall goal of this funded proposal is to dissect the molecular mechanisms of early tumor progression in the prostate. The proposed aims are based on preliminary findings showing that the loss of a specific class of regulatory molecules called microRNAs blocks progression from early hyperplasia to dysplasia in a PTEN knockout model of the disease. The aims themselves are to uncover the underlying microRNAs (aim 1) and microRNA regulated pathways (aim 2) that are normally responsible for progression. Knowing the miRNAs and downstream pathways that cooperate with PTEN loss (the most commonly deleted gene in prostate cancer) has the potential to improve the evaluation of the risk of early progression. The ability to distinguish and treat tumors that are likely to progress will have a broad impact on the disease as it would have the potential to diminish the overdiagnosis and overtreatment of early disease.

Statement of Work:

Specific Aim 1: Uncover miRNAs essential for the suppression of senescence, expansion of basal cells, and tumor progression in the context of Pten loss.

- What miRNAs are upregulated with Pten deletion, but lost with the simultaneous Dgcr8 deletion?
- Which miRNAs are functionally responsible for progression to dysplasia, suppressing senescence and expansion of basal-like cells in the luminal niche?

Specific Aim 2: Use miRNAs to uncover the molecular pathways that cooperate with Pten loss to promote tumor progression.

- What messenger RNAs are regulated by miRNAs during early PCa progression?

The goals for year three as outlined in the statement of work were to:

- Introduction of constructs into mice (months 22-30)
- Aging of mice and phenotypic characterization (months 24-36)

2. KEYWORDS

Prostate Cancer, MicroRNAs, Post-transcriptional Regulation, Progression, Senescence, Basal and Luminal Cells, Transformation.

3. ACCOMPLISHMENTS

We will reference the specific figures in our recent EMBO Reports publication¹ as the supporting data for these key accomplishments. Experimental details are found in the Materials and Methods section¹.

Key Research Accomplishments

- Establishment of a mouse model to study the role of DGCR8-mediated microRNA biogenesis in the background of PTEN-mediated prostate tumor formation. (Figure 1)
- Loss of DGCR8 reduces tumor incidence in PTEN-KO model of prostate cancer. (Figure 2)
- Loss of DGCR8 inhibits the histological progression to dysplasia in the PTEN-KO model of prostate cancer. (Figure 3)
- Basal cell expansion in PTEN-KO prostate cancers required DGCR8 (Figure 4); as did the inhibition of senescence and increase in proliferation. (Figure 5)
- A subset of microRNAs change with PTEN-mediated tumorigenesis. (Figure 6)
- Akt activity and DGCR8 expression are correlated in human prostate cancers. (Figure 7)

Specific Aim1:

Identification of microRNAs differentially regulated following loss of PTEN in mouse epithelium. After developing methods for purifying epithelial cell from the mouse prostates and for measuring microRNAs from minute amounts of sample RNA, we were able to apply these methods to measuring miRNAs in the

prostate epithelium of individual mice. We used flow cytometry to isolate GFP positive cells from mice carrying an inducible GFP reporter, along with inducible alleles for PTEN and a prostate specific cre (Figure 6A). Thus, the GFP cells will be highly enriched for prostate epithelial that are null for PTEN. The cre along with reporter alone was used as normal control. RNA was purified from cells from individual mice yielding 1-10ng RNA per mice. Using a modified sequencing protocol involving a combination of techniques originally described by Tuschl and colleagues² and Yui³ and colleagues, we were able to produce high quality libraries. Next, we developed novel bioinformatics pipelines to evaluate the sequencing results. We identified 17 microRNAs that were differentially regulated following PTEN loss (Figure 6B and 6C). These are strong candidates for microRNAs that normally overcome senescence in Akt activated tumors, the most commonly disrupted pathway in human prostate tumors. Going forward, we plan to evaluate these individual microRNAs. We will be submitting grants to continue this work.

Specific Aim2:

Identification of a statistically significant link between Akt pathway activation and increases in DGCR8 in human primary prostate samples. Reviewers of our original submission to EMBO reports made a very interesting request. While, others previously published and we had our own data showing increased levels of the microRNA biogenesis machinery including DGCR8 with tumor progression, the reviewers wanted to know if DGCR8 increases specifically with Akt activation, the direct consequence of PTEN loss. Thus, we analyzed TCGA data and protein array data for hundreds of human tumors looking for increases in DGCR8 with markers of Akt activation upregulation such as downstream effectors and phosphorylated Akt (Figure 7). To our own surprise, there was a strong association. To our knowledge, this finding provides the first link between a specific oncogenic pathway and the upregulation of the microRNA biogenesis pathway. In the future, we hope to determine if this link is direct or indirect.

Conclusion:

Our findings show that DGCR8 is not required for post-natal maintenance of the mouse prostate. However when combined with a conditional PTEN knockout modes, the loss of Dgcr8 inhibits progression. This block is associated with senescence-associated beta-galactosidase activity. Furthermore there is a correlation between PTEN pathway activation in the form of AKT levels and DGCR8 levels in human prostate cancer samples further supporting the relevance of this model system.

References:

1. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, et al. (2015) DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 16:1219-1232. doi:10.15252/embr.201439925.
2. Williams A, Ben-Dov IZ, Elias R, Mihailovic A, Brown M, et al. (2013) Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. PNAS. 110:4255-4260. doi:10.1073/pnas.1214046110.
3. Zhang A, Lee JE, Riemondy K, Anderson E and Yi R. (2013) High-efficiency RNA cloning enables accurate quantification of miRNA expression by deep sequencing. Genome Biol. 14:R109. doi:10.1186/gb-2013-14-10-r109.

4. IMPACT

Our studies to date demonstrate that there is a requirement for microRNAs for the histological progression of PTEN^{KO}-mediated prostate cancer. As early as 12 weeks there is a reduction in hyperplasia in the PTEN/Dgcr8 double knockouts compared to PTEN knock-out and any further progression is entirely blocked. The block is associated with cell senescence thereby identifying a central role for miRNAs in promoting prostate cancer progression by overcoming this important barrier. As such it provides a targetable node in prostate cancer for treatment. We have uncovered specific microRNAs that are associated with overcoming the senescence block. Potentially even more interesting was the finding that DGCR8 upregulation is associated with Akt activation in human tumors. DGCR8 makes a

complex with Drosha, the enzyme required for miRNA cleavage. Small molecules toward Drosha are being developed by numerous labs. Thus going forward Drosha may be a reasonable target for treating prostate tumors associated with activated Akt, which make up a preponderance of advanced tumors. Of course, blocking Drosha could be harmful to normal tissues as well. However, a partial block may be tolerable for normal tissues by less so by addicted tumors. We aim to put in future grants to study this possibility as well as determine whether specific microRNA inhibitors have therapeutic potential.

5. CHANGES/PROBLEMS

As described in last year's progress report, we ran into several problems measuring microRNAs specifically in the epithelium of the genetically modified mouse prostates. We finally overcame these issues, but it delayed our ability to measure their individual functions. We were still able to make major advances as described above and in our recent publication. Indeed, we made discoveries that we had not even considered at the time when the grant was originally funded. Going forward, we plan to study the role of the individual microRNAs we uncovered along with the potential of targeting the biogenesis pathway itself with the goal of suppressing prostate cancer progression.

6. PRODUCTS:

Our paper was published this year in EMBO Reports¹:

Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, et al. (2015) DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 16:1219-1232. doi:10.15252/embr.201439925.

7. PARCIPIANTS & OTHER COLLABORATING ORGANIZATIONS:

Budget period of: 09/30/2013-09/29/2014:

Name	Robert Blelloch
Project Role	PI
Research Identifier	
Nearest person month	1.2
Contribution to Project:	Dr. Blelloch was responsible for overall coordination of this project. He was involved in the design, interpretation and publication of all experiments.
Funding Support:	DOD

Name	Cassandra Belair
Project Role	Associate Research
Research Identifier	
Nearest person month	5.45
Contribution to Project:	Cassandra Belair has performed all experiments described in preliminary results. She was responsible for all experiments described in proposal.
Funding Support:	DOD

Budget period of: 09/30/2014-09/29/2015:

Name	Robert Blelloch
Project Role	PI
Research Identifier	
Nearest person month	1.26
Contribution to Project:	Dr. Blelloch was responsible for overall coordination of this project. He was involved in the design, interpretation and publication of all experiments.

Funding Support:	DOD
------------------	-----

Name	Cassandra Belair
Project Role	Associate Research
Research Identifier	
Nearest person month	4.4
Contribution to Project:	Cassandra Belair has performed all experiments described in preliminary results. She was responsible for all experiments described in proposal.
Funding Support:	DOD

Name	Jacob Freimer
Project Role	Graduate Student
Research Identifier	
Nearest person month	5.6712
Contribution to Project:	
Funding Support:	DOD

Name	Ron Parchem
Project Role	Postdoc
Research Identifier	
Nearest person month	7
Contribution to Project:	
Funding Support:	DOD

Has there been a change in the active other support of the PD/PIs or Senior Personnel?
No significant to report.

What other organizations were involved as partners? N/A

8. Special Reporting Requirements: N/A

9. APPENDICES:

PDF Reprint of EMBO Reports manuscript attached.

10. SUPPORTING DATA:

NA

DGCR8 is essential for tumor progression following PTEN loss in the prostate

Cassandra D Belair^{1,2,3,*}, Alireza Paikari^{1,2}, Felix Moltzahn^{1,3}, Archana Shenoy^{1,3}, Christina Yau^{4,5}, Marc Dall'Era³, Jeff Simko^{3,6}, Christopher Benz^{4,5} & Robert Blelloch^{1,2,3,6}

Abstract

In human prostate cancer, the microRNA biogenesis machinery increases with prostate cancer progression. Here, we show that deletion of the *Dgcr8* gene, a critical component of this complex, inhibits tumor progression in a *Pten*-knockout mouse model of prostate cancer. Early stages of tumor development were unaffected, but progression to advanced prostatic intraepithelial neoplasia was severely inhibited. *Dgcr8* loss blocked *Pten* null-induced expansion of the basal-like, but not luminal, cellular compartment. Furthermore, while late-stage *Pten* knockout tumors exhibit decreased senescence-associated beta-galactosidase activity and increased proliferation, the simultaneous deletion of *Dgcr8* blocked these changes resulting in levels similar to wild type. Sequencing of small RNAs in isolated epithelial cells uncovered numerous miRNA changes associated with PTEN loss. Consistent with a *Pten*–*Dgcr8* association, analysis of a large cohort of human prostate tumors shows a strong correlation between Akt activation and increased *Dgcr8* mRNA levels. Together, these findings uncover a critical role for microRNAs in enhancing proliferation and enabling the expansion of the basal cell compartment associated with tumor progression following *Pten* loss.

Keywords DGCR8; microRNA; microRNA biogenesis; prostate cancer; PTEN

Subject Categories Cancer; RNA Biology; Stem Cells

DOI 10.15252/embr.201439925 | Received 25 November 2014 | Revised 24 June 2015 | Accepted 27 June 2015

Introduction

Canonical microRNAs (miRNAs) are transcribed as long RNAs called primary miRNAs (pri-miRNA) that undergo two critical processing steps. First, in the nucleus, the pri-miRNA is processed to a precursor-miRNA (pre-miRNA) by the Microprocessor complex consisting of two proteins, DGCR8 and DROSHA. Next, in the

cytoplasm, the pre-miRNA is processed to the mature microRNA duplex by DICER. The levels of the processing machinery are tightly regulated by homeostatic feedback mechanisms in normal tissues [1–4]. However, in cancers, these levels can be dramatically altered (reviewed in [5]). In lung and ovarian cancers, the down-regulation of the biogenesis machinery correlates with poor prognosis, suggesting that miRNAs are suppressing progression of these tumors [6–9]. Indeed, knockdown of the biogenesis machinery can enhance tumorigenicity in an *in vivo* model of lung cancer [9–11]. In contrast, in esophageal and prostate cancer increases in the biogenesis machinery correlate with tumor progression, suggesting a positive effect of enhanced miRNA biogenesis in this tumor type [12–17].

Profiling experiments have shown that miRNAs are mis-regulated in prostate cancer [16,18–23]. However, overlap between data sets has been poor, likely due to the cellular heterogeneity of this tumor type, differences in sample acquisition, and differences in profiling platforms [24,25]. Functional studies for miRNAs in prostate cancer have been mostly performed in cell lines [26,27]. Two studies have tested the roles of miRNA clusters on the prostate *in vivo*. Specifically, inhibition of the miR-15/16 cluster or overexpression of the miR-106/25 cluster promotes cell proliferation in an otherwise normal prostate [28,29].

The prostate-specific *Pten* (phosphatase and tensin homolog deleted on chromosome 10) knockout mouse model (*Pten*^{Δ/Δ}) shows a stereotypical pattern of tumor progression [30–32]. This is characterized by early hyperplasia, followed by dysplasia and architectural disorganization of prostate tubules, and rare microinvasion into surrounding tissue. The model is highly relevant to human prostate cancer as 30% of localized disease and 60% of metastatic disease are associated with *Pten* loss [33]. *Pten* loss results in enhanced senescence in early anterior prostate lesions [34]. Suppression of senescence by combining *Pten* loss with *P53* or *P27* loss accelerates prostate tumor progression [34,35].

Considering that the miRNA biogenesis machinery is increased with prostate cancer progression in humans, we wanted to test the global role of miRNAs in the *Pten*^{Δ/Δ} model. *Pten*^{loxP/loxP} [31] and *Dgcr8*^{loxP/loxP} [36,37] conditional mice were combined with a

1 The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California – San Francisco, San Francisco, CA, USA

2 Center for Reproductive Sciences, University of California – San Francisco, San Francisco, CA, USA

3 Department of Urology, University of California – San Francisco, San Francisco, CA, USA

4 Department of Medicine, University of California – San Francisco, San Francisco, CA, USA

5 Buck Institute for Research on Aging, Novato, CA, USA

6 Department of Anatomic Pathology, University of California – San Francisco, San Francisco, CA, USA

*Corresponding author. Tel: +1 415 476 2838; E-mail: cassandra.belair@ucsf.edu

prostate-specific cre (*Probasin-Cre*) [38]. Analysis of resulting mice showed that deletion of *Dgcr8* did not influence early epithelial hyperplasia, but severely disrupted further progression to dysplasia. Associated with this inhibition of progression was a block in the expansion of cells expressing basal cell markers and a failure to suppress senescence. Therefore, miRNA biogenesis plays essential roles in progression following *Pten* loss. Profiling of the mouse epithelium uncovered numerous miRNAs whose expression was altered with *Pten* loss. The *Dgcr8* knockout model should provide a powerful means to dissect the role of these and other miRNAs along with their downstream targets. Relevance of this model to human tumors is supported by a statistically significant correlation between AKT activation downstream of PTEN and increased levels of DGCR8 across a large cohort of prostate cancer samples.

Results

Dgcr8 loss reduces *Pten*-knockout tumor formation

To test the role of DGCR8 and hence canonical miRNAs in prostate cancer progression, we turned to the *Pten* and *Dgcr8* conditional knockout mouse models. Specifically, probasin-cre [38] (*Pb-Cre*), which is expressed throughout the prostate epithelium beginning 1 week following birth, was crossed to *Pten^{loxP/loxP}* [31] and *Dgcr8^{loxP/loxP}* [36,37] conditional knockout alleles, referred from here on as *Pten^{Δ/Δ}* and *Dgcr8^{Δ/Δ}*, respectively. Immunostaining confirmed loss of nuclear DGCR8 protein in the epithelium of *Dgcr8^{Δ/Δ}* and *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* prostates at both 12 and 32 weeks of age using two independent antibodies and methods (Fig 1A). To confirm down-regulation of miRNAs associated with *Dgcr8* loss, RNA was isolated from prostates of *Pten^{Δ/Δ}* and *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* mice. *Dgcr8* mRNA levels were significantly down in the *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* relative to *Pten^{Δ/Δ}* (Fig 1B). To test miRNA levels, a multiplex qRT-PCR reaction was performed for 80 miRNAs. Fifty-five of these miRNAs were expressed in at least two of the three *Pten^{Δ/Δ}* samples. Of the 55 miRNAs, 41 were consistently down in the knockouts (Fig 1C). The remaining 14 likely reflect miRNAs highly expressed among the non-epithelial cell contaminants; for example, miR-22 is expressed in fibroblasts [39,40]. These data are consistent with an expected loss of miRNA biogenesis following *Pb-cre*-driven deletion of *Dgcr8* in the prostatic epithelium. Furthermore, phosphorylated-AKT (pAKT) was

upregulated in both *Pten^{Δ/Δ}* and *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* prostates relative to their *Pten* wild-type counterparts showing that *Dgcr8* loss did not alter the effect of *Pten* deletion on the AKT pathway (Figs 1D and EV1).

Next, we asked whether *Dgcr8* loss altered tumor development in the *Pten* null prostate epithelium. We collected prostates from mice aged from 10 to 52 weeks, which were separated into two cohorts—a young cohort (10–14 weeks of age) and an old cohort (32–44 weeks of age). In the young cohort, sixteen of the seventeen *Pten^{Δ/Δ}* mice had developed visible prostate tumors, while only four of the fourteen *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* had done so (Fig 2A and B). Mice were allowed to age to discern whether there was a delay versus a block in tumorigenesis in the absence of *Dgcr8*. In the older cohort, all *Pten^{Δ/Δ}* mice had large tumors, while eight of twelve *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* mice had developed discernable tumors, a statistically significant decrease (Fig 2A and C). Of note, the *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* mice tended to be slightly older than the *Pten^{Δ/Δ}* mice in the old cohort, but still had fewer tumors (Fig EV2A). Furthermore, the *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* tumors, when present, were generally smaller (Fig 2A). *Dgcr8* loss alone produced normal appearing prostates at all ages examined (Figs 2 and EV2A). Together, these data show that *Dgcr8* is not essential for postnatal growth of the prostate, but does suppress tumor development following *Pten* loss.

Dgcr8 loss inhibits histological progression

Loss of *Pten* results in a stereotypical histological progression over time, initially showing hyperplasia but then progressing to severe dysplasia consistent with high-grade PIN (prostatic intraepithelial neoplasia) [30–32]. To test the effect of *Dgcr8* loss on histological progression, prostates from the different genetic backgrounds were sectioned, stained with hematoxylin and eosin, and evaluated by two independent pathologists blinded to genotype [41]. Tissues were scored based on structural and cellular changes in the glandular and stromal compartments and parsed into three groups: normal, benign hyperplasia, and advanced dysplasia (Fig 3A). Hyperplasia was defined as tubules showing epithelial cell expansion often bridging across the lumen, whereby cells appeared relatively normal with little increase in mitoses or necrosis (Fig 3A, middle panels). Dysplasia was defined as expansion of abnormal appearing cells with common mitoses, solid sheets of tumor cell growth, nuclear atypia, and necrosis, all consistent with a higher-grade tumor (Fig 3A, right panels).

Figure 1. *Pb-cre*-driven deletion of *Dgcr8* and *Pten*.

- Staining for DGCR8 protein in prostates. Upper images: immunohistochemical staining using the Aviva Systems Biology antibody (scale bar, 100 μ m). Wild-type and *Pten^{Δ/Δ}* prostates have DGCR8-positive nuclei in both the basal and luminal cells as well as surrounding stromal cells. *Dgcr8^{Δ/Δ}* and *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* prostates show diminished DGCR8 nuclear staining in both basal and luminal cells, but not stromal cells. Cytoplasmic signal is non-specific. Representative images of at least two mice of each genotype from the old cohort were analyzed. Lower images: immunofluorescent staining for DGCR8 expression using the Proteintech Group antibody (scale bar, 100 μ m). DAPI and DGCR8 channels from the same field of view are shown. DAPI staining shows the position of nuclei. The inset shows representative cells 3 $\times$ zoomed. Arrows indicate cells with positive nuclear stain, and arrowheads indicate cells lacking nuclear stain. Representative images of at least two mice of each genotype from the young cohort were analyzed.
- Relative levels of *Dgcr8* transcript in *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* versus *Pten^{Δ/Δ}* alone. qRT-PCR for *Dgcr8* exon 3 expression was performed on RNA prepared from frozen sections of 3 mice of each genotype.
- Relative expression levels of 55 miRNAs in *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* versus *Pten^{Δ/Δ}* alone. Multiplex qRT-PCR data for three individuals of each genotype as in (B). C_t values were normalized to *Sno202* levels. Error bars represent standard deviation.
- Representative confocal images of pAKT staining. Immunofluorescent staining of pAKT expression reveals strong expression in *Pten^{Δ/Δ}* and *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* prostates compared to wild type and *Dgcr8^{Δ/Δ}*. AKT phosphorylation is directly downstream of PTEN and is activated upon PTEN loss. Shown are representative images taken from at least two mice per genotype in the old cohort using the Olympus confocal microscope as described in Materials and Methods (scale bar, 100 μ m). See Fig EV1 for representative low-magnification images from young and old cohorts.




Figure 1.




Figure 2. Loss of *Dgcr8* reduces tumor incidence in *Pten*^{Δ/Δ} model of prostate cancer.

A Representative images of prostates from each genotype. Upper panels: young cohort; lower panels: old cohort. Note large bilateral tumors in old *Pten*^{Δ/Δ} prostates and smaller bilateral tumors in the young *Pten*^{Δ/Δ} animals. Other genotypes show examples of normal appearing prostates (scale bar, 100 μm). See Fig EV2A for breakdown of individual mice by age and genotype.

B, C Quantification of tumor incidence (green) represented as percentage of total in the young (B) and old (C) cohorts. The number of mice with each phenotype is shown within bars. Statistical differences were calculated by the Fisher's exact test. n.s. *P* > 0.05, **P* < 0.05, ***P* < 0.005, ****P* < 0.0005.

In the young cohort, eight of nine *Pten*^{Δ/Δ} prostates examined and five of eight *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ} showed diffuse hyperplasia (Fig 3B). None of these prostates had evidence of dysplasia. In the old cohort, eight out of eleven *Pten*^{Δ/Δ} mice showed severe dysplasia consistent with high-grade PIN (Fig 3C). Furthermore, a single *Pten*^{Δ/Δ} mouse showed areas suspicious for invasion, although frank invasive carcinoma was never observed (Appendix Fig S1). In contrast, only one of twelve *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ} prostates showed evidence of dysplasia. Instead, ten of twelve showed hyperplasia and one of the twelve showed normal histology. The single dysplastic and single normal *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ} prostate were each from mice aged 44 weeks (Fig EV2B). Double knockout mice aged 1 year still failed to progress to dysplasia (Appendix Fig S2, Fig EV2), suggesting that progression was blocked rather than simply delayed. Importantly, *Dgcr8* loss alone had no discernable histological phenotype. Therefore, these findings show that while *Dgcr8* is not required for stability of the normal adult prostatic epithelium or for the development of

hyperplasia in *Pten*^{Δ/Δ}, it is important for cytologic progression from hyperplasia to dysplasia in the context of *Pten* loss.

Basal cell expansion associated with *Pten* loss is reversed by concomitant loss of *Dgcr8*

Similar to the human prostate, the normal murine prostate epithelium consists of a basal and a luminal cell layer with rare neuroendocrine cells. The basal cells are in direct contact with the basal lamina forming a discontinuous layer around the periphery of the gland and express the cytokeratin CK5. The luminal cells are larger with distinct apical polarity, form a continuous layer of cells overlying the basal cells, and express the cytokeratin CK8. This architectural organization is lost in *Pten*^{Δ/Δ} prostates [32]. In particular, the luminal cells become multilayered and the CK5-positive basal cells expand out of their normal peripheral niche into the more luminal regions.




Figure 3. Loss of *Dgcr8* inhibits histological progression to dysplasia in the *Pten*^{Δ/Δ} background.

A Categorization of histological phenotypes. Shown are representative images of different histological phenotypes at low and high magnification (scale bar, 100 μm). All sections were stained with hematoxylin/eosin. See text for description of histological features used to define normal, hyperplasia, and dysplasia categories.

B, C Characterization and quantification of histology on representative young mice from Fig 2B and old mice in Fig 2C. All slides were evaluated and scored by two pathologists blinded to genetic background. Statistical differences were calculated by a modified Freeman-Halton extension of the Fisher's exact test. n.s. *P* > 0.05, **P* < 0.05, ***P* < 0.005, ****P* < 0.0005. See Fig EV2B for breakdown of individual mice by age and genotype.

To identify a potential role for miRNAs in this phenotype, we stained for CK5 and CK8 in the different genetic backgrounds (Fig 4A, Appendix Fig S3). As previously described, *Pten* loss resulted in the migration of basal-like cells from the basal lamina into the more luminal regions (Figs 4A and EV3). The number of cells positive for the basal and luminal markers was up in the *Pten*^{Δ/Δ} relative to wild-type prostates (Fig 4B). Loss of *Dgcr8* alone did not influence the architecture or the number of CK5 and CK8 staining cells within the tubules (Fig 4A and B). However, in the *Pten*^{Δ/Δ} background the loss of *Dgcr8* dramatically altered the phenotype. Indeed, the CK5-positive basal cell compartment of the double knockouts looked strikingly similar to that of the wild-type and *Dgcr8* alone knockouts (Figs 4A and EV3F). In contrast, the

expansion in the number of CK8-positive luminal cells was similar between *Pten*^{Δ/Δ} and *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ} prostates (Fig 4B). Therefore, while *Dgcr8* loss alone does not alter the size or architecture of basal and luminal cell compartments, it does block the expansion and mis-localization of the CK5-positive cells normally seen in the *Pten* null background.

DGCR8 is essential for promoting proliferation and inhibiting senescence in late-stage tumors

PTEN loss has been reported to promote senescence in the anterior prostate, which then diminishes with tumor progression [34,42]. To evaluate the effect of miRNA loss on this phenotype, we stained for




Figure 4. *Dgcr8* is required for *Pten*^{Δ/Δ}-mediated basal cell expansion.

A Representative confocal images of basal (CK5; green) and luminal (CK8; red) cell populations in indicated genotypes from the old cohort. Nuclei are stained with the DNA dye ToPro3 (blue) (scale bar, 100 μ m).

B Quantification of basal and luminal cell compartments. The extent of basal and luminal expansion was measured by counting the number of cells staining positive for either CK5 (basal cells) or CK8 (luminal cells) in 63 $\times$ images taken at the junction of the dorsal–lateral and anterior prostate lobes. Four images from four individual mice were evaluated per genotype for a total of at least 16 microscopic fields of view per genotype. Mean $\pm$ standard deviation is shown. The statistical significance was calculated using Student's t-test. n.s. $P > 0.05$, * $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$.

the senescence marker beta-galactosidase (SA- β -gal) in sections of the dorsal and lateral prostate lobes (Fig 5A). In the young cohort, SA- β -gal staining was consistently detected in all genotypes. This is in contrast to the previous reports that described minimal activity in wild-type prostates. This difference may reflect regional differences in the degree of senescence. However, similar to the previous reports, there was a reduction in SA- β -gal in the $Pten^{\Delta/\Delta}$ prostates as the mice aged (Fig 5B). Furthermore, the older $Pten^{\Delta/\Delta}$ mice showed significantly lower numbers of SA- β -gal cells relative to their wild-type, $Dgcr8^{\Delta/\Delta}$, and $Pten^{\Delta/\Delta}$ $Dgcr8^{\Delta/\Delta}$ counterparts (20 versus typically greater than 40 percent of the cells). Consistent with SA- β -gal, the number of cells staining for the proliferation marker Ki67 was greatly reduced in the wild-type, $Dgcr8$ knockout, and the $Pten$: $Dgcr8$ double knockout mice relative to $Pten$ knockout alone (Figs 5C and EV4). In particular, $Pten^{\Delta/\Delta}$ mice showed a large number of proliferative cells in the luminal region, which were rarely seen in the other genetic backgrounds. The percentage of Ki67-positive nuclei was quantified in samples from the old cohort showing a significant difference between $Pten^{\Delta/\Delta}$ and $Pten^{\Delta/\Delta}$ $Dgcr8^{\Delta/\Delta}$ samples (Fig 5D). Therefore, $Dgcr8$ is essential for the decrease in senescence and increase in proliferation seen at late stages of tumor progression in the $Pten$ -knockout mice. Cleaved

caspase-3 staining showed only very rare apoptotic cells in all genotypes and thus is unlikely to play a major role (Appendix Fig S4). Together, these data suggest that DGCR8 is required to enable progression in the $Pten$ null background.

microRNA changes in *Pten* null tumors

To identify miRNAs that are altered with $Pten$ loss, we crossed the $R26^{lox-stop-lox-YFP}$ reporter allele into the wild-type and $Pten^{\Delta/\Delta}$ lines allowing for isolation of the corresponding prostate epithelial cells (Fig 6A). The specific isolation of the epithelial cells is critical since profiling of whole tumor tissue can lead to erroneous interpretations [43]. RNA libraries were prepared from YFP-positive cells from 3 wild-type and 3 $Pten^{\Delta/\Delta}$ prostates and submitted for Illumina sequencing. We found 21 microRNAs whose expression was significantly different (Fig 6B). Seventeen of these miRNAs were expressed at substantial levels in at least one of the two groups [i.e. average of > 100 cpm, all of which showed highly significant changes in expression (Fig 6C)]. Five of these microRNAs (miR-139, 183, 210, 31, and 93) were upregulated with $Pten$ loss and thus are strong candidates for playing a positive role in promoting progression in these prostates.




Figure 5. Increased senescence and decreased proliferation in *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ} relative to *Pten*^{Δ/Δ} prostates.

A Senescence: Staining for SA-β-gal (blue). Counter-stained with Nuclear Fast Red. Representative images at 10× magnification are shown.

B Quantification of SA-β-gal-positive cells. Two slides of all old mice shown in Fig 2C were counted. The percentages of SA-β-Gal-positive cells were calculated as the ratio of β-Gal-positive out of 500 cells total counted per animal. A total of 250 cells were counted on both the right and the left proximal anterior prostate and adjacent dorsal-lateral prostate in the section. Four mice of each genotype were counted. Mean ± SD is shown. Student's t-test was used to calculate statistical significance. Wild type, *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ}, and *Dgcr8*^{Δ/Δ} were not statistically different from each other. n.s. *P* > 0.05, **P* < 0.05, ***P* < 0.005, ****P* < 0.0005.

C Representative confocal images of proliferation marker Ki67 green with DAPI-stained nuclei overlay (scale bar, 100 μm).

D Quantification of Ki67 staining. The percentage of Ki67 was calculated by determining the ratio of Ki67-positive to all ToPro3-labeled nuclei in the prostate glands. At least four images from four individuals of each genotype were counted. Images were taken in approximately the same location in each prostate at the junction of the dorsal-lateral and anterior prostate lobes. Mean ± SD is shown. Student's t-test was used to calculate statistical significance. Wild type, *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ}, and *Dgcr8*^{Δ/Δ} were not statistically different from each other. n.s. *P* > 0.05, **P* < 0.05, ***P* < 0.005, ****P* < 0.0005.




Figure 6.

Figure 6. microRNA changes associated with Pten-mediated tumorigenesis.

- A Scheme to isolate Pten-deficient epithelial cells from mouse prostate. Prostates were isolated from 12-week-old transgenic mice expressing *Probasin-Cre* and the *Rosa26^{lox-stop-lox-YFP}* reporter allele plus and minus the *Pten^{fllox/fllox}* allele. YFP-positive cells were isolated using fluorescence-activated cell sorting technology. RNA was isolated and small RNA libraries were submitted for deep sequencing analysis.
- B Volcano scatter plot of log₂-fold difference between wild type and *Pten^{Δ/Δ}* versus log₁₀ *P*-values. microRNAs with differences > 2-fold and *q*-value < 0.05 are highlighted and labeled. *Q*-values were determined using Benjamini–Hochberg procedure.
- C Scatterplot of log₂ counts per million (cpm) expression values of subset of miRNAs with *q*-values < 0.05 and average counts in at least one group of > 100 cpm. The black bar represents the mean of the three values for each genotype.

Source data are available online for this figure.

Akt activity and Dgcr8 levels are correlated in human prostate cancers

Previously, it had been shown that the microRNA biogenesis machinery, including Dgcr8, is increased in human prostate cancers relative to normal prostate tissue [5,15,16]. To confirm these findings, we performed IHC for DGCR8 on human prostate cancer samples. Interestingly, staining showed DGCR8 levels in tumor cells to be similar to levels found in normal basal cells, but increased relative to normal luminal cells (Fig EV5). To expand on these findings, we asked whether there is a direct correlation between DGCR8 levels and activation of AKT pathway among human prostate cancers. To infer AKT activity, the PARADIGM algorithm was applied to RNA profiling data on 334 prostate adenocarcinoma (PRAD) samples from the Cancer Genome Atlas Program to determine integrated pathway levels (IPLs) [44,45]. A significant positive correlation was uncovered between *DGCR8* expression and PARADIGM-inferred AKT2 IPLs whether evaluated as a continuous measurement (Spearman's rank correlation (Rho) $\rho = 0.25$, $P = 4.77E-6$) or binned into distinct activity levels (Kruskal–Wallis test $P = 5.69E05$) (Fig 7A and B). Two hundred of these TCGA PRAD cases had reverse-phase protein array (RPPA) data allowing for independent measurement of AKT activity based on pAKT (pT308 and pS473) levels. While *DGCR8* expression showed no correlation with total AKT protein level ($\rho = 0.00$, $P = 0.99$), it had a significant positive correlation with pAKT (pT308) levels ($\rho = 0.13$, and $P = 0.04$) as well as a strong trend for correlation with pAKT (S473) ($\rho = 0.12$, $P = 0.06$), further supporting an association between AKT activation and *DGCR8* (Fig 7C). Together, these findings support the relevance of the mouse model to human prostate cancer.

Discussion

Our findings show that *Dgcr8* is not required for the post-natal maintenance of the mouse prostate. However, when combined with a *Pten* knockout model, the loss of *Dgcr8* inhibits tumor progression. This block is associated with inhibition of basal cell compartment expansion and increased senescence-associated beta-galactosidase activity. In contrast, early hyperplasia associated with *Pten* loss is unaffected by *Dgcr8* loss. microRNAs are down in the double knockout relative to *Pten* knockout alone, consistent with DGCR8's known requirement in canonical miRNA biogenesis [37,46]. It has been proposed that Dgcr8 has broad roles in RNA processing beyond microRNAs, based on HITS-CLIP data showing interaction of Dgcr8 with a large fraction of the coding and non-coding transcriptome

[47]. However, more recent work evaluating not only binding but also cleavage of targets *in vivo* shows that cleavage of non-miRNA targets is rare and of unclear significance [48]. Indeed, Dgcr8 levels track very closely with overall pri-miRNA levels diminishing risk of off-target cleavage [4]. Therefore, the defect in tumor progression in the *Pten^{Δ/Δ} Dgcr8^{Δ/Δ}* mice is most easily explained by depletion in tumor-promoting miRNAs.

Interestingly, a number of microRNA families including the miR-106/25, the miR-17-92, and miR-23b clusters promote early hyperplasia in prostate by targeting *Pten* itself [28,49]. These findings, together with those reported here, suggest two important roles for miRNA control in prostate tumor development (Appendix Fig S5). In the presence of *Pten*, miRNAs can promote early hyperplasia by suppressing *Pten* post-transcriptionally. If *Pten* is genetically lost, this first stage of tumorigenesis occurs in a miRNA-independent fashion. However, with *Pten* loss, further tumor progression is initially delayed by the induction of senescence, a protective adaptation to otherwise uncontrolled growth, in older animals [34]. Eventually, senescence is overcome and tumor progression occurs in a miRNA-dependent fashion. A role for miRNAs and the miRNA biogenesis machinery in both enhancing and overcoming senescence has been described in other settings [50–52]. The miRNAs responsible for overcoming the senescence block in the current model remain to be determined. However, profiling of the *Pten* null epithelial cells uncovered a number of miRNAs that were upregulated following PTEN loss including miR-139, 183, 210, 31, and 93. Future studies functionally testing each of these miRNAs in the context of PTEN loss will be important in the determination of their roles in progression.

The importance of miRNAs in promoting prostate cancer progression is supported by the increase in the biogenesis machinery, at the level of both pri- to pre-miRNA (DGCR8/DROSHA) and pre- to mature miRNA (DICER) processing [15–17]. Similar increases are seen in esophageal cancer [12,13]. However, the opposite is seen in other tumors including lung and ovarian [6–9]. The differences between these tumors may reflect the dominant population of miRNAs found within the tumor cells of origin. If tumor-suppressive miRNAs predominate (as would be found in a more differentiated cells), it would be beneficial for the cells to decrease miRNA biogenesis. In contrast, if tumor-promoting miRNAs were the major population, then increased miRNA biogenesis would provide a selective advantage. Indeed, the major role of decreased Dicer levels in Ras-induced lung cancer model appears to be the suppression of let-7 processing, a well-known tumor-suppressive miRNA found in most differentiated tissues [53]. Interestingly, we find a correlation between AKT activity and *DGCR8* levels across a large cohort of human prostate cancers. Thus, an alternative to




Figure 7. Association between DGCR8 expression and PARADIGM-inferred AKT2 integrated pathway level (IPL) in human prostate adenocarcinoma.

- A Scatterplot of DGCR8 mRNA expression versus PARADIGM-inferred AKT2 IPL in 334 TCGA PRAD cases.
 B Boxplot showing DGCR8 mRNA expression within AKT2 IPLs defined subgroups.
 C Scatterplot of DGCR8 mRNA expression versus pAKT-pT308 protein levels.

tumor type is that the decrease or increase in the biogenesis machinery is associated with the underlying genetic changes. That is, while increased Ras activity may require decreased miRNA production for progression, Akt activity may require increased miRNA biogenesis. Going forward, it will be important to evaluate such relationships.

Pb-cre-driven *Dgcr8* deletion alone did not produce a discernable phenotype in terms of histology, basal or luminal cell number, proliferation or senescence. These findings contrast with a publication evaluating the effect of *Pb-cre*-driven deletion of *Dicer* [54]. *Dicer* deletion resulted in apoptosis of luminal cells and concomitant increase in proliferation of the basal cells, neither of which were seen in the *Dgcr8* knockout prostates. While *Dgcr8* and *Dicer* are both essential for the processing of canonical miRNAs, *Dicer* has additional roles [55]. In particular, *Dicer* is essential for the processing of endo-siRNAs and non-canonical miRNAs including mirtrons and shRNAs [56]. Therefore, the difference in phenotype between *Dgcr8* and *Dicer* loss may be explained by roles for these other subclasses of small RNAs in the prostate. The inhibitory effect of *Dicer* loss on luminal cells was not overcome by *Pten* loss in this model again consistent with additional roles for *Dicer* [57]. It will be interesting to search for DGCR8-independent small RNAs in the prostate and determine whether their roles can explain the differences in phenotype following *Dgcr8* and *Dicer* loss.

What and how microRNAs are regulating prostate cancer remains unclear. The findings reported here suggest two potential roles in post-initiation stages of tumor progression, one in basal cell expansion and the other in controlling senescence. The correlation of the loss of basal cell expansion and decreased tumor progression suggests a central role of the basal cells providing a supportive role in progression, possibly acting as a reservoir for secondary hits. Indeed, many findings have suggested that basal cells can provide the cell of origin for prostate cancer [58–61]. Other findings would suggest that rare luminal stem-like cells can also be efficiently transformed following specific deletion of *Pten* [62,63]. In our double knockout model, we find that the luminal cells expand in the absence of miRNAs, but many become senescent.

However, the most dramatic phenotype is in the basal cell layer, where the additional loss of *Dgcr8* reverses the basal cell expansion and migration seen with *Pten* alone. Once again, knowing the miRNAs required for progression and cells in which they function should help resolve this issue of the source of the cancer-initiating cells.

The *Dgcr8* knockout model provides an opportunity to uncover the miRNAs that are regulating these processes by using an add-back approach [64–66]. That is, individual miRNAs can be reintroduced one at a time in the otherwise knockout background and tested for rescue of different phenotypes such as basal cell expansion or decreased senescence. This approach has the advantage that it removes the complicating issues of redundancy and cross-reactivity between miRNAs enabling one to focus on one miRNA at a time.

Materials and Methods

Mice were bred and maintained in accordance with UCSF guidelines. Prostates were collected, frozen in OCT, sectioned on a cryostat, and stained using standard protocols. OCT blocks were manually dissected for RNA preparation. miRNA levels were measured by multiplex qRT-PCR.

Mice

Generation of the *Dgcr8*^{loxp/loxp} mice in our laboratory has been described previously, and mice are available from Jackson Labs (MMRRC:32051 <http://jaxmice.jax.org/query>) [36,37]. *Pten*^{loxp/loxp} [31] and *PBCre4* [38] were crossed with *Dgcr8*^{loxp/loxp} to obtain the appropriate alleles. The reporter allele *R26*^{lox-stop-lox-YFP} was crossed in to appropriate lines for the small RNA sequencing experiments [67]. Mice were maintained in B6 background. All mice were genotyped from tail DNA by PCR at weaning and at tissue collection using published primers. Mice were housed in the AALAC-accredited (#001084) UCSF Laboratory Animal Research Center. PHS Assurance #A3400-01.

Necropsy and histopathology

Tissue was collected from mice of various genotypes as described previously [41]. Dissected prostates were immediately photographed and then fresh-frozen in OCT (Thermo Scientific). Briefly, the block of tissue was dissected, wiped dry, photographed, and then submerged in OCT in a manner to allow for taking histological sections through the dorsal and lateral prostate lobes. The entire OCT block was submerged in methylbutane (Fisher) that was pre-cooled on dry ice. After 5 min, the block was stored at -20 or -80°C prior to sectioning. A total of $7\text{ }\mu\text{m}$ sections were stored at -80°C until processed for histology or immunostaining. Standard hematoxylin (Sigma) and eosin-Y (Richard-Allen Scientific) staining was performed. At least two independent sections from each tumor were provided to a urologic pathologist for evaluation and characterization. This and all subsequent cellular analysis was performed on sections confirmed to contain dorsal and lateral lobes of the prostate. For all of these samples, the pathologist was blinded as to genotype and tissues were evaluated and classified according to the Bar Harbor Classification scheme [41]. Prostate organ images at 12 weeks old were acquired on an Olympus MVX10 using a 0.63X objective with a DP71 camera and at 32 weeks old on a Leica MZ16 using a 0.63X reducer and 0.71X objective with a DFC320 camera. Histological images were acquired on a Leica DM1000 10 $\times$ or 40 $\times$ objective with a DFC290 camera.

Dgcr8 transcript and miRNA expression analysis

Prostate tissue was collected by manual dissection of OCT blocks. RNA was prepared using Trizol reagent (Invitrogen). RNA was quantified on NanoDrop spectrophotometer. Quality of RNA samples was evaluated on an Agilent Bioanalyzer using a Nano kit (Agilent). Dgcr8 qPCR was performed following RT (Invitrogen) on an ABI 7900 real-time PCR machine using SYBR Green mix as previously published; primers were as follows: qDGCR8-F AGGTCTCTGTGCTC CCAAGAAG, qDGCR8-R TGGTCATCATTGGCTGTACACTT [2,37]. Multiplex qRT-PCR for miRNA quantitation was performed exactly according to the published protocol, on the Fluidigm Biomark microfluidics platform [68]. RT and qPCR was performed as previously described using custom-made primers [37].

Senescence activity

Senescence-associated beta-galactosidase (SA- β -gal) was measured as previously described on sections containing the dorsal and lateral lobes [69]. Briefly, slides were fixed 10 min in 4% PFA, rinsed with PBS, and then stained with X-gal solution at pH 6.0 overnight at 37°C . Slides were rinsed with PBS, counter-stained lightly with hematoxylin and eosin, dehydrated, and mounted in Cytoseal-60 (Richard-Allen Scientific). Senescence staining was also performed with similar results using the Cellular Senescence Assay Kit (Millipore), counterstained with Nuclear Fast Red (Vector Laboratories), and mounted in glycerol. Images were acquired on a Leica DM1000 10 $\times$ objective with a DFC290 camera.

Immunostaining

Mouse samples were stained for DGCR8 using two techniques. Samples from the old cohort were prepared using the Vectastain

elite rabbit ABC kit following the manufacturer's instructions after blocking endogenous peroxidase activity with hydrogen peroxide and incubation with the rabbit anti-human-DGCR8 primary antibody (Aviva Systems Biology, ARP40984) overnight at 4°C . All slides were incubated in the substrate for the same amount of time. Color images were acquired on a Leica DM1000 40 $\times$ objective with a DFC290 camera. Samples from both the cohorts were prepared for immunofluorescent staining by first performing antigen retrieval in 3 mM sodium citrate buffer in a steaming rice cooker for 20 min. After the samples cooled to room temperature, they were rinsed with PBS, blocked with PBS/0.1% Tween-20/10% goat serum, and then incubated in the primary rabbit anti-mouse DGCR8 antibody (Proteintech Group 10996-1-AP) overnight at 4°C . The slides were then rinsed with PBS twice for 5 min and briefly with PBS/0.1% Tween-20 and then incubated 2 h in the appropriate Alexa Fluor-labeled secondary antibody (Invitrogen) at 1:500 dilution in the same blocking buffer. Nuclei were stained with DAPI. Images were captured using Metamorph (Molecular Dynamics) running a Leica DMI4000B 63 $\times$ objective and DFC350FX camera.

Immunofluorescent staining was done essentially as for DGCR8 using the following primary antibodies: cleaved caspase-3, rabbit anti-human (Cell Signaling Technology 9664 1:200); cytokeratin 5, rabbit anti-mouse CK5 (Covance, clone AF138, 1:200); cytokeratin 8, mouse anti-human CK8 (Covance, clone HK-8, 1:50); Ki67, rabbit anti-mouse Ki67 (Thermo, clone SP6, 1:200); and pAKT (Ser473) (Cell Signaling technology D9E, 1:50). ToPro3 (Invitrogen) or DAPI (Invitrogen) was used as a DNA/nuclear counterstain in all fluorescent experiments. Samples for confocal analysis were stained for 10 min with ToPro3 (1:10,000), dipped in water, and then mounted in fluoromount-G (Southern Biotech), and images were captured on a Zeiss LSM 5 Pascal confocal microscope using the 63 $\times$ objective. Samples for epi-fluorescent analysis were stained with DAPI, dipped in water, and then mounted in ProLong Gold (Invitrogen). Images were captured using Metamorph (Molecular Dynamics) running a Leica DMI4000B and DFC350FX camera.

Quantification of molecular markers

Quantification of CK5, CK8, and Ki67 was done on slides prepared from old cohort samples using fluorescent images collected on a Zeiss LSM 5 Pascal confocal microscope (63 $\times$ objective). Four 63 $\times$ confocal images per mouse and at least three mice per genotype were analyzed. The images were taken from the dorsal-lateral region proximal to the anterior prostate. The percentage of CK5-, CK8-, or Ki67-positive cells was calculated by counting the number of positive cells out of total ToPro3-labeled nuclei. Counting was constrained to the prostate ducts; stromal cells were not included in the analysis.

SA- β -gal staining was quantified by counting the number of positive cells out of 250 cells from both the right and the left dorsal-lateral prostate for 500 cells total. Four mice for each genotype were quantified. For this analysis, samples were from the old cohort and all stained in the same batch using the published technique [69].

Differential miRNA expression

Prostates were collected from four wild-type and five *Pten*^{loxP/loxP} mice also expressing *PBCre4* and *R26*^{lox-stop-lox-YFP}. Prostates were

dissected from the seminal vesicles and urinary tract organs and then prepared for FACS analysis [70]. RNA was prepared using the Qiagen micro miRNeasy kit. Small RNA libraries were prepared as previously described [71] with additional modifications to optimize ligations [72]. The detailed protocol will be posted at www.BlellochLab.ucsf.edu. Pooled small RNA libraries were sequenced on a Illumina HiSeq 2500 machine. Resulting reads were trimmed using CutAdapt (DOI: 10.14806/ej.17.1.200) (parameters: -u 2 -max-n 0 -m 17 -M 36) and mapped as previously described [73].

Statistical analysis

The Freeman-Halton extension of the Fisher's exact test was used to test whether the differences in tumor formation and histological grouping per genotype were statistically significant. Student's *t*-test was used to test whether the differences in immunostaining between genotypes were statistically significant.

Mapped small RNA reads were normalized as counts per million reads mapping to pre-miRNA hairpins. Exploratory analysis using PCA, hierarchical clustering, and comparison of median and variance between samples was used to remove outlier samples. *P*-values were determined using rowttests on those rows with log₂ counts > 0 and then corrected for multiple hypothesis testing using qvalue package in R.

Integration of copy number, mRNA expression, and pathway interaction data was performed on 334 prostate adenocarcinoma (PRAD) samples from The Cancer Genome Atlas (TCGA) program using the PARADIGM algorithm [44,45]. Level 3 RSEM normalized expression and Level 4 GISTIC thresholded copy number data were obtained from Firehose, and pathway interaction data included pathways from the NCI-PID, BioCarta, and Reactome databases. From these data, the PARADIGM algorithm infers an integrated pathway level (IPL) for each pathway feature that reflects its activity in a tumor sample relative to the median activity across all tumors.

Correlation between log₂-scaled mRNA expression levels of DGCR8 and the PARADIGM-inferred AKT1, AKT2, and AKT3 IPL was assessed using Spearman's rank correlation. In addition, we subdivided the data set based on the AKT2 IPL into three groups (median: IPL = 0, low: IPL < 0, high: IPL > 0) and compared the DGCR8 mRNA expression between these three groups using the Kruskal–Wallis test.

Expanded View for this article is available online:
<http://embor.embopress.org>

Acknowledgements

We would like to thank members of the Blelloch Laboratory for critical reading of the manuscript. We would like to thank Samuel Chadwick and Samir Qurashi for their assistance with the mouse husbandry and tissue preparation and Muhammad Danial for his technical assistance in preparing the mouse sequencing libraries. This work was supported by funds to CDB and RB from DOD (PC110468). CDB received additional support from a UCSF Prostate Cancer Center Junior Faculty Award, JS from the UCSF Prostate SPORE, NIH Grant P50CA89520, and FM from the Wissenschaftlich Urologische Gesellschaft eV.

Author contributions

CDB contributed to all figures except Fig 7. AP contributed to Figs 3 and 5, Figs EV2 and EV4. FM contributed to Figs 1 and 5. JS contributed to Figs 3

and 5, Fig EV5, Appendix Figs S1 and S2. AS contributed to Fig 6. CY and CB contributed to Fig 7. MD contributed to Fig EV5. CDB and RB conceived the project and CDB wrote the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Shenoy A, Blelloch R (2009) Genomic analysis suggests that mRNA destabilization by the microprocessor is specialized for the auto-regulation of Dgcr8. *PLoS ONE* 4: e6971
- Han J, Pedersen JS, Kwon SC, Belair CD, Kim YK, Yeom KH, Yang WY, Haussler D, Blelloch R, Kim VN (2009) Posttranscriptional crossregulation between Drosha and DGCR8. *Cell* 136: 75–84
- Triboulet R, Chang HM, Lapierre RJ, Gregory RI (2009) Post-transcriptional control of DGCR8 expression by the microprocessor. *RNA* 15: 1005–1011
- Barad O, Mann M, Chapnik E, Shenoy A, Blelloch R, Barkai N, Hornstein E (2012) Efficiency and specificity in microRNA biogenesis. *Nat Struct Mol Biol* 19: 650–652
- Lin S, Gregory RI (2015) MicroRNA biogenesis pathways in cancer. *Nat Rev Cancer* 15: 321–333
- Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM *et al* (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. *N Engl J Med* 359: 2641–2650
- Pampalakis G, Diamandis EP, Katsaros D, Sotiropoulou G (2010) Down-regulation of dicer expression in ovarian cancer tissues. *Clin Biochem* 43: 324–327
- Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y, Yanagisawa K, Yatabe Y, Takamizawa J, Miyoshi S, Mitsudomi T *et al* (2005) Reduced expression of Dicer associated with poor prognosis in lung cancer patients. *Cancer Sci* 96: 111–115
- Rakheja D, Chen KS, Liu Y, Shukla AA, Schmid V, Chang TC, Khokhar S, Wickiser JE, Karandikar NJ, Malter JS *et al* (2014) Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. *Nat Commun* 2: 4802
- Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. *Nat Genet* 39: 673–677
- Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J, Kirsch DG, Golub TR, Jacks T (2009) Dicer1 functions as a haploinsufficient tumor suppressor. *Genes Dev* 23: 2700–2704
- Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Ando T, Mori R, Takashima N, Ogawa R *et al* (2006) RNAseN regulates cell proliferation and affects survival in esophageal cancer patients. *Clin Cancer Res* 12: 7322–7328
- Yoo NJ, Hur SY, Kim MS, Lee JY, Lee SH (2010) Immunohistochemical analysis of RNA-induced silencing complex-related proteins AGO2 and TNRC6A in prostate and esophageal cancers. *APMIS* 118: 271–276
- Akagi I, Miyashita M, Ishibashi O, Mishima T, Kikuchi K, Makino H, Nomura T, Hagiwara N, Uchida E, Takizawa T (2011) Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. *Dis Esophagus* 24: 523–530

15. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R (2006) Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. *Am J Pathol* 169: 1812–1820
16. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Res* 68: 6162–6170
17. Shaikhibrahim Z, Lindstrot A, Ochsenfahrt J, Fuchs K, Wernert N (2013) Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. *Int J Mol Med* 31: 21–25
18. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. *Oncogene* 27: 1788–1793
19. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T (2007) MicroRNA expression profiling in prostate cancer. *Cancer Res* 67: 6130–6135
20. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S, Senzer N, Eklund AC, Han J, Nemunaitis J (2009) MicroRNA profile analysis of human prostate cancers. *Cancer Gene Ther* 16: 206–216
21. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. *Proc Natl Acad Sci USA* 103: 2257–2261
22. Song H, Liu Y, Pan J, Zhao ST (2013) Expression profile analysis reveals putative prostate cancer-related microRNAs. *Genet Mol Res* 12: 4934–4943
23. Hart M, Nolte E, Wach S, Szczyrba J, Taubert H, Rau TT, Hartmann A, Grasser FA, Wullich B (2014) Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. *Mol Cancer Res* 12: 250–263
24. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K (2010) MicroRNAs and cancer: current state and future perspectives in urologic oncology. *Urol Oncol* 28: 4–13
25. Mestdagh P, Hartmann N, Baeriswyl L, Andreassen D, Bernard N, Chen C, Cheo D, D'Andrade P, DeMayo M, Dennis L et al (2014) Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. *Nat Methods* 11: 809–815
26. Gandellini P, Folini M, Zaffaroni N (2009) Towards the definition of prostate cancer-related microRNAs: where are we now? *Trends Mol Med* 15: 381–390
27. Cannistraci A, Di Pace AL, De Maria R, Bonci D (2014) MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples. *Biomed Res Int* 2014: 146170
28. Polisenio L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G et al (2010) Identification of the miR-106b–25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. *Sci Signal* 3: ra29
29. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C et al (2008) The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. *Nat Med* 14: 1271–1277
30. Lesche R, Groszer M, Gao J, Wang Y, Messing A, Sun H, Liu X, Wu H (2002) Cre/loxP-mediated inactivation of the murine Pten tumor suppressor gene. *Genesis* 32: 148–149
31. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T et al (2003) Pten dose dictates cancer progression in the prostate. *PLoS Biol* 1: E59
32. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell* 4: 209–221
33. Sarker D, Reid AH, Yap TA, de Bono JS (2009) Targeting the PI3K/AKT pathway for the treatment of prostate cancer. *Clin Cancer Res* 15: 4799–4805
34. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W et al (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature* 436: 725–730
35. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R et al (2008) A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. *Cancer Cell* 14: 146–155
36. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R, Reinhardt F, Liao R, Krieger M, Jaenisch R et al (2009) Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. *Circ Res* 105: 585–594
37. Suh N, Baehner L, Moltzahn F, Melton C, Shenoy A, Chen J, Blleloch R (2010) MicroRNA function is globally suppressed in mouse oocytes and early embryos. *Curr Biol* 20: 271–277
38. Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech Dev* 101: 61–69
39. Jazbutyte V, Fiedler J, Kneitz S, Galuppo P, Just A, Holzmann A, Bauersachs J, Thum T (2013) MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. *Age* 35: 747–762
40. Xu D, Takeshita F, Hino Y, Fukunaga S, Kudo Y, Tamaki A, Matsunaga J, Takahashi RU, Takata T, Shimamoto A et al (2011) miR-22 represses cancer progression by inducing cellular senescence. *J Cell Biol* 193: 409–424
41. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R et al (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. *Cancer Res* 64: 2270–2305
42. Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G et al (2014) Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. *Cell Rep* 9: 75–89
43. Chivukula RR, Shi G, Acharya A, Mills EW, Zeitels LR, Anandam JL, Abdelnaby AA, Balch GC, Mansour JC, Yopp AC et al (2014) An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. *Cell* 157: 1104–1116
44. Sedgewick AJ, Benz SC, Rabizadeh S, Soon-Shiong P, Vaske CJ (2013) Learning subgroup-specific regulatory interactions and regulator independence with PARADIGM. *Bioinformatics* 29: i62–i70
45. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM (2010) Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. *Bioinformatics* 26: i237–i245

46. Wang Y, Medvid R, Melton C, Jaenisch R, Blelloch R (2007) DGC8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. *Nat Genet* 39: 380–385
47. Macias S, Plass M, Stajuda A, Michlewski G, Eyraes E, Caceres JF (2012) DGC8 HITS-CLIP reveals novel functions for the Microprocessor. *Nat Struct Mol Biol* 19: 760–766
48. Seong Y, Lim DH, Kim A, Seo JH, Lee YS, Song H, Kwon YS (2014) Global identification of target recognition and cleavage by the microprocessor in human ES cells. *Nucleic Acids Res* 42: 12806–12821
49. Tian L, Fang YX, Xue JL, Chen JZ (2013) Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals *in vitro*. *PLoS ONE* 8: e75885
50. Abdelmohsen K, Srikantan S, Kang MJ, Gorospe M (2012) Regulation of senescence by microRNA biogenesis factors. *Ageing Res Rev* 11: 491–500
51. Feliciano A, Sanchez-Sendra B, Kondoh H, Lleonaert ME (2011) MicroRNAs regulate key effector pathways of senescence. *J Aging Res* 2011: 205378
52. Gorospe M, Abdelmohsen K (2011) MicroRegulators come of age in senescence. *Trends Genet* 27: 233–241
53. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. *Proc Natl Acad Sci USA* 105: 3903–3908
54. Zhang L, Zhang B, Valdez JM, Wang F, Ittmann M, Xin L (2010) Dicer ablation impairs prostate stem cell activity and causes prostate atrophy. *Stem Cells* 28: 1260–1269
55. Babiarz JE, Blelloch R (2009) Small RNAs - their biogenesis, regulation and function in embryonic stem cells. *StemBook* [Internet]. Cambridge, MA: Harvard Stem Cell Institute
56. Babiarz JE, Ruby JG, Wang Y, Bartel DP, Blelloch R (2008) Mouse ES cells express endogenous shRNAs, siRNAs, and other Microprocessor-independent, Dicer-dependent small RNAs. *Genes Dev* 22: 2773–2785
57. Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis MT, Creighton CJ, Ittmann MM, Xin L (2014) A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. *Oncogene* 33: 3099–3108
58. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON (2010) Identification of a cell of origin for human prostate cancer. *Science* 329: 568–571
59. Lawson DA, Xin L, Lukacs R, Xu Q, Cheng D, Witte ON (2005) Prostate stem cells and prostate cancer. *Cold Spring Harb Symp Quant Biol* 70: 187–196
60. Lukacs RU, Lawson DA, Xin L, Zong Y, Garraway I, Goldstein AS, Memarzadeh S, Witte ON (2008) Epithelial stem cells of the prostate and their role in cancer progression. *Cold Spring Harb Symp Quant Biol* 73: 491–502
61. Mulholland DJ, Xin L, Morim A, Lawson D, Witte O, Wu H (2009) Lin-Sca-1+CD49^{high} stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. *Cancer Res* 69: 8555–8562
62. Wang X, Kruthof-de Julio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C, Shen MM (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. *Nature* 461: 495–500
63. Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM (2013) Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice. *Am J Pathol* 182: 975–991
64. Wang Y, Baskerville S, Shenoy A, Babiarz JE, Baehner L, Blelloch R (2008) Embryonic stem cell-specific microRNAs regulate the G1-S transition and promote rapid proliferation. *Nat Genet* 40: 1478–1483
65. Melton C, Judson RL, Blelloch R (2010) Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. *Nature* 463: 621–626
66. Steiner DF, Thomas MF, Hu JK, Yang Z, Babiarz JE, Allen CD, Matloubian M, Blelloch R, Ansel KM (2011) MicroRNA-29 regulates T-box transcription factors and interferon-gamma production in helper T cells. *Immunity* 35: 169–181
67. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev Biol* 1: 4
68. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton JF, Carroll P, Blelloch R (2011) Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. *Cancer Res* 71: 550–560
69. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O *et al* (1995) A biomarker that identifies senescent human cells in culture and in aging skin *in vivo*. *Proc Natl Acad Sci USA* 92: 9363–9367
70. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON (2010) Isolation, cultivation and characterization of adult murine prostate stem cells. *Nat Protoc* 5: 702–713
71. Williams Z, Ben-Dov IZ, Elias R, Mihailovic A, Brown M, Rosenwaks Z, Tuschl T (2013) Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. *Proc Natl Acad Sci USA* 110: 4255–4260
72. Zhang Z, Lee JE, Riemondy K, Anderson EM, Yi R (2013) High-efficiency RNA cloning enables accurate quantification of miRNA expression by deep sequencing. *Genome Biol* 14: R109
73. Shenoy A, Danial M, Blelloch RH (2015) Let-7 and miR-125 cooperate to prime progenitors for astroglialogenesis. *EMBO J* 34: 1180–1194

Expanded View Figures




Figure EV1. Phosphorylated-AKT expression correlates with genetic *Pten* loss.

A, B Representative epi-fluorescent images from the young (A) and old (B) cohort at low magnification. Upper panels in green show pAKT Ser373 expression. Lower panels in blue show corresponding DAPI images (scale bar, 500 μ m).




Figure EV2. Tumor and histological breakdown of all mice in the study by age and genotype.

In main figures, these mice were divided into two cohorts based on age. The young cohort is aged 10–12 weeks and the old cohort is aged 32–44 weeks. Note that the *Pten*^{Δ/Δ} mice in the old cohort tended to be younger, but still had more advanced cancer phenotype than double knockout mice.

A Tumor phenotype as seen on gross inspection for all mice in Fig 2B and C. Blue, no tumor; green, tumor.

B Histology phenotype as seen on H&E sections for all mice in Fig 3B and C. Blue, normal; green, hyperplasia; purple, dysplasia.




Figure EV3. *Dgcr8* is required for *Pten*^{ΔΔ}-mediated basal cell expansion.

A, B Representative low-magnification epi-fluorescent images of basal (CK5; green) and luminal (CK8; red) cell populations in indicated genotypes from the young cohort (A) and the old cohort (B). Nuclei are stained with the DAPI (blue) (scale bars, 500 μ m). Note expansion of basal cells in old *Pten* null mice, which is not seen in other genotypes. Quantification of old mice is shown in Fig 5B.




Figure EV4. Decreased proliferation in *Pten*^{ΔΔ} *Dgcr8*^{ΔΔ} relative to *Pten*^{ΔΔ} prostates.

A, B Representative low-magnification epi-fluorescent images of Ki67 (green) staining in prostates from the young cohort (A) and from the old cohort (B). Nuclei are stained with the DAPI (blue) (scale bar, 500 μ m). Note increased proliferation in both young and old *Pten* null mice relative to other genotypes. Quantification of old mice is shown in Fig 5D.




Figure EV5. DGCR8 is expressed preferentially in the basal cells of normal human prostates and aberrantly expressed in the luminal cells of tumors.

Representative IHC images of DGCR8 staining in human prostate cancers. The normal gland in each panel is demarcated by the dotted line; L indicates lumen. DGCR8-positive basal cells lining the normal prostate gland are indicated by the arrowhead. Note that the overlying luminal cells are DGCR8 negative. Adjacent low grade (left panel) and high grade (right panel) showing increasing levels of DGCR8 protein in the tumor cells over normal cells.

Appendix Table Of Contents

1. Appendix Figure Legends	Page 2
2. Appendix References	Page 3
3. Appendix Figure S1	Page 4
4. Appendix Figure S2	Page 5
5. Appendix Figure S3	Page 6
6. Appendix Figure S4	Page 7
7. Appendix Figure S5	Page 8

Appendix Supplementary Figure Legends:

Appendix Figure S1. Rare *Pten*^{Δ/Δ} tumor areas suspicious for invasion.

A) Representative histological image of an area suspicious for invasion. (scale bar = 500um)

B) Higher power magnification of *in situ* tumor most commonly seen in these prostates. (scale bar = 100um)

C) Small nests of tumor cells within stroma display paradoxical increased cell cytoplasm and lack of basement membrane and basal cell layer, consistent with invasion per consensus criteria [1]. (scale bar = 100um)

Appendix Figure S2. Tumor progression is still inhibited after one year.

Representative histological images from one year old wild type and *Pten*^{Δ/Δ} *Dgcr8*^{Δ/Δ} double knockout prostates show that tumor progression is still halted at hyperplasia. (scale bar = 500um, insets = 100um)

Appendix Figure S3. *Dgcr8* is required for *Pten*^{Δ/Δ} –mediated basal cell expansion.

Immunofluorescence analysis of basal (CK5) and luminal (CK8) cell populations demonstrated an increased CK5-positive population in *Pten*^{Δ/Δ} which are not found in *Pten*^{Δ/Δ}; *Dgcr8*^{Δ/Δ} prostates. Nuclei are stained with the DNA dye ToPro3. Individual confocal channels are shown to clarify the extent of CK5 and CK8 expansion. Note that *Dgcr8*^{Δ/Δ} appear the same as wild type indicating that loss of DGCR8 does not itself impact number or location of CK5 or CK8 positive cells.

Appendix Figure S5. Representative confocal images of apoptosis marker cleaved caspase 3 (green) with nuclei labeled blue. Specific staining indicated by the arrow in each panel. (scale bar = 100um).


Appendix Figure S4. Model for role of miRNAs in tumor progression following loss of PTEN.

Our data supports a model of prostate tumor progression following the loss of Pten activity whereby the initial stages of tumor growth and development of hyperplasia proceeds in a microRNA independent manner. However the progression of these tumors to the dysplastic phenotype requires DGCR8-dependent microRNA biogenesis.


Appendix References

1. Shappell SB *et al* (2004) Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. *Cancer Res* **64**: 2270-2305


Appendix Figure S1




Appendix Figure S2



Appendix Figure S3



Appendix Figure S4



Appendix Figure S5

